Get started
Author

Roser Escrig

Observed names: Escrig, Roser, R Escrig, Roser Escrig-Sarreta
ORCID: 0009-0009-1095-4039
Observed ORCID: 0009-0009-1095-4039
OpenAlex ID: A5029713011
Concurrent outbreaks of mpox in Africa—an update
2024 · Camila G Beiras, Emile Malembi, et al. · The Lancet · 89
PDF
Gut microbiome signatures linked to HIV-1 reservoir size and viremia control
2022 · Alessandra Borgognone, Marc Noguera-Julian, et al. · Microbiome · 64
PDF
Therapeutic Vaccination Refocuses T-cell Responses Towards Conserved Regions of HIV-1 in Early Treated Individuals (BCN 01 study)
2019 · Beatriz Mothe, Christian Manzardo, et al. · EClinicalMedicine · 64
PDF
Improvement in bone mineral density after switching from tenofovir to abacavir in HIV-1-infected patients with low bone mineral density: two-centre randomized pilot study (OsteoTDF study)
2014 · Eugènia Negredo, Pere Domingo, et al. · Journal of Antimicrobial Chemotherapy · 49
Clinical presentation and epidemiological assessment of confirmed human mpox cases in DR Congo: a surveillance-based observational study
2025 · Emile Malembi, Roser Escrig-Sarreta, et al. · The Lancet · 28
Switching from tenofovir to abacavir in HIV-1-infected patients with low bone mineral density: changes in bone turnover markers and circulating sclerostin levels
2015 · Eugènia Negredo, Adolfo Diez-Pérez, et al. · Journal of Antimicrobial Chemotherapy · 28
Single oral dose of maraviroc does not prevent ex-vivo HIV infection of rectal mucosa in HIV-1 negative human volunteers
2015 · Josep Coll, José Moltó, et al. · AIDS · 18
Time-resolved diffused optical characterization of key tissue constituents of human bony prominence locations
2015 · Sanathana Konugolu Venkata Sekar, Andrea Farina, et al. · Diffuse Optical Spectroscopy and Imaging · 18
PDF
Effect of Maraviroc Intensification on HIV-1-Specific T Cell Immunity in Recently HIV-1-Infected Individuals
2014 · Ai Kawana-Tachikawa, Josep M. Llibre, et al. · PLoS ONE · 18
PDF
Study protocol of a randomized controlled trial to assess safety of teleconsultation compared with face-to-face consultation: the ECASeT study
2023 · Alejandro Rodríguez-Molinero, Gerard Carot-Sans, et al. · Trials · 4
PDF
Target Trial Emulation of the Modified Vaccinia Ankara-Bavarian Nordic Vaccine for Pre-Exposure Mpox Prevention in At-Risk Populations
2025 · Clara Suñer, Roser Escrig-Sarreta, et al. · Vaccines · 3
PDF
Corrigendum to ‘Therapeutic vaccination refocuses T-cell responses towards conserved regions of HIV-1 in early treated individuals (BCN 01 study)’ EClinicalMedicine 11 (2019) 65–80
2020 · Beatriz Mothe, Christian Manzardo, et al. · EClinicalMedicine · 2
PDF
Reasons for using and efficacy of raltegravir in salvage regimens without protease inhibitors in clinical practice
2010 · JM Llibre, E Martínez, et al. · Journal of the International AIDS Society · 1
PDF
Strengthening tuberculosis clinical trial implementation: operational challenges, lessons learned, and consensus recommendations from a Delphi study
2026 · Ayoub Ez-Zari, Cristina Prat Aymerich, et al. · BMC Public Health
Evaluation of dual path platform optical density in relation to RPR titers and serological response in syphilis: a cross-sectional and longitudinal study
2026 · Sara Buezo, Roser Escrig-Sarreta, et al. · International Journal of Infectious Diseases
PDF
Repunte de pacientes con sífilis durante el embarazo
2026 · Susana Muñoz, Oriol Mitjà, et al. · Enfermedades Emergentes
Works count: 20
Citation count: 386
H-index: 9
I10-index: 9
Year
Topic
Type